| Risperdal Consta (risperidone depot formulation) / J&J |
NCT00261430: A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone. |
|
|
| Completed | 4 | 650 | US | GAIN Acceptance Approach | Janssen, LP | Schizophrenia | | 10/04 | | |
NCT00215579: Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence |
|
|
| Completed | 4 | 64 | US | Depot Risperidone Microsphere (Consta) | Duke University, Janssen, LP | Schizophrenia, Schizoaffective Disorder | 04/06 | 04/06 | | |
NCT00314613: Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal |
|
|
| Terminated | 4 | 30 | US | Antipsychotic/Risperidone Consta | Duke University, Janssen, LP | Schizophrenia | 12/06 | | | |
NCT00216528: A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres |
|
|
| Completed | 4 | 527 | RoW | risperidone | Janssen Korea, Ltd., Korea | Schizophrenia | | 04/07 | | |
NCT00216632: A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™) |
|
|
| Completed | 4 | 99 | Europe | risperidone | Janssen Pharmaceutica N.V., Belgium | Schizophrenia, Psychotic Disorders | 07/07 | 07/07 | | |
NCT00369239: Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis |
|
|
| Completed | 4 | 303 | Europe | risperidone long acting injectable | Janssen Pharmaceutica N.V., Belgium | Schizophrenia, Psychotic Disorders, Schizoaffective Disorder | | 11/07 | | |
NCT01726335: Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia |
|
|
| Completed | 4 | 53 | RoW | Risperidone prolonged release, - Risperdal consta | Janssen-Cilag Ltd. | Schizophrenia | 03/08 | 03/08 | | |
NCT00246259: A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis |
|
|
| Completed | 4 | 77 | Canada | Risperidone long-acting injection (LAI), Oral Antipsychotic | Janssen-Ortho Inc., Canada | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders | 12/08 | 12/08 | | |
NCT00299702: Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia |
|
|
| Completed | 4 | 355 | US | Abilify, Risperidal Consta | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen, LP | Schizophrenia, Psychotic Disorders | 01/09 | 01/09 | | |
NCT00526877: An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment |
|
|
| Completed | 4 | 31 | RoW | Risperidone, Risperdal Consta | Johnson & Johnson Taiwan Ltd | Schizophrenia, Schizoaffective Disorders | 01/09 | 01/09 | | |
| Completed | 4 | 50 | US | Risperdal (risperidone) Consta, Risperidone long-acting injectible, Treatment as usual, Usual care | Vanderbilt University, Ortho-McNeil Janssen Scientific Affairs, LLC | Bipolar Disorder | 02/09 | 02/09 | | |
NCT01855074: An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders |
|
|
| Completed | 4 | 80 | RoW | Risperidone | Janssen-Cilag Ltd. | Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder | 02/09 | 02/09 | | |
NCT00256997 / 2005-004383-23: A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication |
|
|
| Terminated | 4 | 167 | Canada, Europe, RoW | Risperidone long-acting injection (LAI), Oral atypical Antipsychotic | Janssen-Ortho Inc., Canada | Schizophrenia | 04/09 | 04/09 | | |
NCT00130923: Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder |
|
|
| Completed | 4 | 95 | US | Risperidone Long Acting, Risperdal Consta, oral risperidone, Risperdal | Dartmouth-Hitchcock Medical Center, Janssen, LP | Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse | 06/09 | 07/10 | | |
NCT00216671: Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode |
|
|
| Completed | 4 | 220 | Europe, RoW | early initiation of treatment with Risperdal Consta, routine initiation of treatment with Risperdal Consta | Janssen Pharmaceutica N.V., Belgium | Schizophrenia | 12/09 | 12/09 | | |
NCT00378092 / 2015-001221-16: A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode |
|
|
| Completed | 4 | 33 | RoW | Oral risperidone, Risperidone Long-Acting Injection (RLAI), Risperdal consta | Janssen Cilag N.V./S.A. | Schizophrenia | 03/10 | 03/10 | | |
NCT00992407: An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 4 | 75 | RoW | Risperidone long acting injectables, Risperdal Consta, Risperidone tablets, Risperdal | Janssen Korea, Ltd., Korea | Schizophrenia | 12/10 | 12/10 | | |
NCT00975611: Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation |
|
|
| Terminated | 4 | 6 | US | Amantadine Hydrochloride, USP, Symmetrel, Placebo, Symmetrel placebo | David C. Henderson, MD, Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia, Schizoaffective Disorder | 01/12 | 01/12 | | |
NCT00539071: High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone |
|
|
| Completed | 4 | 160 | US | long-acting injectable risperidone, long acting injectable risperidone, Risperidone Consta | Northwestern University, Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia, Schizoaffective Disorder | 05/12 | 05/12 | | |
NCT00330551: Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia |
|
|
| Completed | 4 | 126 | US | Oral Risperidone, Risperdal, Risperidone in Long-Acting Injectable Form (Consta), Risperdal Consta | University of California, Los Angeles, National Institute of Mental Health (NIMH), Janssen Scientific Affairs, LLC | Schizophrenia | 11/12 | 11/12 | | |
NCT00333177: Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia |
|
|
| Completed | 4 | 92 | US | Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperdal, Risperidone, administered via injection (RLAI), Risperdal Consta | University of California, Los Angeles, National Institute of Mental Health (NIMH), Janssen Scientific Affairs, LLC | Schizophrenia | 01/13 | 01/13 | | |
2005-004621-25: Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta? |
|
|
| | 4 | 40 | Europe | RISPERDAL Consta/25mg, RISPERDAL Consta/37,5mg, RISPERDAL Consta/50mg, Risperdal 1mg Tablets, F109, F5, RISPOLEPT CONSTA 25 mg, RISPOLEPT CONSTA 37.5 mg, RISPOLEPT CONSTA 50 mg, RISPOLEPT 1 mg, RISPOLEPT CONSTA 25 mg, RISPOLEPT CONSTA 37.5 mg, RISPOLEPT CONSTA 50 mg, RISPOLEPT 1 mg | Janssen-Cilag Medical Affairs EMEA, Janssen-Cilag B.V., Janssen-Cilag EMEA, Janssen Cilag EMEA, JANSSEN-CILAG EMEA, Janssen-Cilag International N.V., Janssen-Cilag Ltd | Schizophrenia, schizoaffective disorder | | 10/07 | | |
NCT02472652: Aripiprazole, Abilify Maintena Collaborative Clinical Protocol |
|
|
| Terminated | 4 | 2 | US | Abilify Maintena, Aripiprazole | Gazda, Thomas D., M.D., PC, Otsuka America Pharmaceutical | Sexual Dysfunction | 12/16 | 03/17 | | |
